Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment [0.03%]
在欧洲全面利用生物类似药的整体优势—第二部分：付款人如何确保健康发展的生物类似药市场环境
Jorge Mestre-Ferrandiz,Marcin Czech,Josef S Smolen et al.
Jorge Mestre-Ferrandiz et al.
Introduction: Biosimilars have improved access to biologic medicines; however, historical thinking may jeopardize the viability of future markets. Areas c...
Joanna Thorn,Kirsty Garfield
Joanna Thorn
Drug pricing and transparency in Europe and the United States: what is it and how does it work? [0.03%]
欧洲和美国的药品定价与透明度：它的内容及其运作方式是什么？
Steven Simoens,Mondher Toumi
Steven Simoens
Introduction: As drug prices are viewed to be opaque, there have been increasing societal demands on policy and decision makers to implement initiatives that promote drug price transparency. ...
Social care data in the UK; current landscape, challenges, and future recommendations [0.03%]
英国的社会护理数据；现状、挑战和未来建议
Diana Mendes,Robert Wood,Monica Seif et al.
Diana Mendes et al.
Objectives: Social care in the United Kingdom (UK) refers to care provided due to age, illness, disability, or other circumstances. Social care provision offers an intermediary step between hospital discharge and sufficie...
Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis [0.03%]
使用MiToS分期系统进行肌萎缩侧索硬化经济评估的可行性评价
Paulos Gebrehiwet,Saurabh Aggarwal,Ozlem Topaloglu et al.
Paulos Gebrehiwet et al.
Objectives: This study assessed the feasibility of using the Milano-Torino staging (MiToS) system for conducting economic evaluation to measure health outcomes in amyotrophic lateral sclerosis (ALS). ...
Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework [0.03%]
从政府长期角度看比利时儿童免疫规划的财政分析
Nikos Kotsopoulos,André Bento-Abreu,Goran Bencina et al.
Nikos Kotsopoulos et al.
Objectives: A public economic framework was used to explore lifetime government costs and benefits in relation to the Pediatric Immunization Program (PIP) in Belgium based on cases and deaths averted. ...
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data [0.03%]
斯洛文尼亚直接糖尿病相关医疗保健支出：基于人口层面数据的近期演变和未来预测
Petra Došenović Bonča,Dalibor Gavrić,Karmen Janša et al.
Petra Došenović Bonča et al.
Objective: The burden of diabetes on individuals, healthcare systems, and society must be explored to improve and sustain diabetes care. With this aim, we estimated both past and future diabetes-related direct health expe...
Adapting Health Technology Assessment agency standards for surrogate outcomes in early stage cancer trials: what needs to happen? [0.03%]
癌症早期阶段试验中健康技术评估机构关于替代结局的标准制定：需要哪些改变？
Kristian Thorlund,Cal Shephard,Lisa Machado et al.
Kristian Thorlund et al.
Introduction: An avalanche of early stage cancer clinical trials is coming. The majority of these solely use surrogate outcomes that have not been validated against a target outcome of interest (e.g. overall survival). Cu...
Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective [0.03%]
在欧洲全面捕获生物类似药的价值-第1部分：历史的角度
Jorge Mestre-Ferrandiz,Marcin Czech,Josef S Smolen et al.
Jorge Mestre-Ferrandiz et al.
Introduction: Approved biosimilars exhibit comparable efficacy, safety, and immunogenicity to reference products. This report provides perspectives on the societal value of biosimilars within Europe and potential factors ...
Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore [0.03%]
Sacituzumab Govitecan与化疗在新加坡用于治疗转移性三阴性乳腺癌的成本效用分析
Boon Piang Cher,Sharon Goh,Mohamed Ismail Abdul Aziz et al.
Boon Piang Cher et al.
Objective: To assess the cost-effectiveness of sacituzumab govitecan for treating relapsed or refractory metastatic triple-negative breast cancer (TNBC) in Singapore. ...